SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    R. A. Overman, M. L. Gourlay, C. L. Deal, J. F. Farley, M. A. Brookhart, J. B. Layton, Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis, Osteoporosis International, 2015, 26, 5, 1515

    CrossRef

  2. 2
    J. M. Albaum, L. E. Lévesque, A. S. Gershon, G. Liu, S. M. Cadarette, Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996–2012, Osteoporosis International, 2015,

    CrossRef

  3. 3
    Laurence Fardet, Irene Petersen, Irwin Nazareth, Monitoring of Patients on Long-Term Glucocorticoid Therapy, Medicine, 2015, 94, 15, e647

    CrossRef

  4. 4
    Moshe Praver, Benjamin C. Kennedy, Jason A. Ellis, Randy D’Amico, Christopher E. Mandigo, Severity of presentation is associated with time to recovery in spinal epidural lipomatosis, Journal of Clinical Neuroscience, 2015, 22, 8, 1244

    CrossRef

  5. 5
    Clément Morin, Laurence Fardet, Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug. A cross-sectional online survey of 820 patients, Clinical Rheumatology, 2015,

    CrossRef

  6. 6
    Vital to monitor, prevent and treat metabolic and cardiovascular adverse events induced by long-term systemic glucocorticoid therapy, Drugs & Therapy Perspectives, 2015,

    CrossRef

  7. 7
    S. A. Morgan, E. L. McCabe, L. L. Gathercole, Z. K. Hassan-Smith, D. P. Larner, I. J. Bujalska, P. M. Stewart, J. W. Tomlinson, G. G. Lavery, 11 -HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess, Proceedings of the National Academy of Sciences, 2014, 111, 24, E2482

    CrossRef

  8. 8
    Georgina M Russell, Stafford L Lightman, Can side effects of steroid treatments be minimized by the temporal aspects of delivery method?, Expert Opinion on Drug Safety, 2014, 13, 11, 1501

    CrossRef

  9. 9
    Anat Ben-Shlomo, James Mirocha, Stephanie M. Gwin, Annika K. Khine, Ning-Ai Liu, Renee C. Sheinin, Shlomo Melmed, Clinical Factors Associated with Biochemical Adrenal-cortisol Insufficiency in Hospitalized Patients, The American Journal of Medicine, 2014, 127, 8, 754

    CrossRef

  10. 10
    Hildur Skuladottir, Allen J. Wilcox, Chen Ma, Edward J. Lammer, Sonja A. Rasmussen, Martha M. Werler, Gary M. Shaw, Suzan L. Carmichael, Corticosteroid use and risk of orofacial clefts, Birth Defects Research Part A: Clinical and Molecular Teratology, 2014, 100, 6
  11. 11
    Natalia O Kuchuk, Jos N Hoes, Johannes WJ Bijlsma, Johannes WG Jacobs, Glucocorticoid-induced osteoporosis: an overview, International Journal of Clinical Rheumatology, 2014, 9, 3, 311

    CrossRef

  12. 12
    René Rizzoli, Emmanuel Biver, Glucocorticoid-induced osteoporosis: who to treat with what agent?, Nature Reviews Rheumatology, 2014, 11, 2, 98

    CrossRef

  13. 13
    Michele Iudici, Serena Fasano, Daniela Iacono, Barbara Russo, Giovanna Cuomo, Gabriele Valentini, Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries, Clinical Rheumatology, 2014, 33, 2, 153

    CrossRef

  14. 14
    Laurence Fardet, Bruno Fève, Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events, Drugs, 2014, 74, 15, 1731

    CrossRef

  15. 15
    Robert A. Overman, Joshua C. Toliver, Jun-Yen Yeh, Margaret L. Gourlay, Chad L. Deal, United States Adults Meeting 2010 American College of Rheumatology Criteria for Treatment and Prevention of Glucocorticoid-Induced Osteoporosis, Arthritis Care & Research, 2014, 66, 11